SI-BONE, a San Jose, Calif.-based medical device company, has received the CE mark for its iFuse Implant System, according to a Science 2.0 report.
The iFuse is a minimally invasive surgical system including titanium implants. The implants are coated with a porous plasma spray to regulate and decrease implant motion.
The system is indicated for use by the FDA for fracture fixation of large bones and large bone fractures of the pelvis.
Read the Science 2.0 report about iFuse.
Read other coverage on SI-BONE:
- SI-BONE Closes $11M Financing for Commercial and Clinical Expansion
- SI-BONE Begins Post-Market Clinical Experience of iFuse Implant Device
- SI-BONE Launches iFuse Implant System in Europe
The iFuse is a minimally invasive surgical system including titanium implants. The implants are coated with a porous plasma spray to regulate and decrease implant motion.
The system is indicated for use by the FDA for fracture fixation of large bones and large bone fractures of the pelvis.
Read the Science 2.0 report about iFuse.
Read other coverage on SI-BONE:
- SI-BONE Closes $11M Financing for Commercial and Clinical Expansion
- SI-BONE Begins Post-Market Clinical Experience of iFuse Implant Device
- SI-BONE Launches iFuse Implant System in Europe